No Data
No Data
Morgan Stanley's (NYSE:MS) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Alternative "Blind Box" is on fire! Banco Santander (SAN.US) seizes the opportunity to sell off 60 billion euros in risk Assets.
Banco Santander is able to remove 60 billion euros (equivalent to 63 billion dollars) of risk-weighted Assets from its balance sheet this year.
Morgan Stanley: The sale of Intime by BABA-SW may bring potential special dividends.
Morgan Stanley released a research report stating that Alibaba-SW (09988) is selling Intime for 7.4 billion yuan, which is expected to result in an accounting loss of 9.3 billion yuan. Morgan Stanley believes that the cash proceeds may contribute to a potential special dividend before the end of this fiscal year, similar to the group’s actions last year. Morgan Stanley thinks that the sale of Intime aligns with the management’s strategy to focus on core Business and potentially divest from offline Retail Trade. Considering the well-known decline in asset value, the recorded loss should not surprise the market, especially since the loss is non-cash and non-recurring.
Morgan Stanley: Maintains "Shareholding" rating for HANSOH PHARMA with a Target Price of 24 Hong Kong dollars.
Morgan Stanley released a research report stating that it gives HANSOH PHARMA (03692) a "Shareholding" rating, with a Target Price of HK$24. HANSOH PHARMA announced that it has entered into a Global exclusive licensing agreement with Merck, granting them the Global exclusive license for the development, production, and commercialization of the preclinical oral small molecule GLP-1 receptor agonist HS-10535, involving an upfront payment of $0.112 billion, as well as milestone payments and royalties based on product sales of up to $1.9 billion. Morgan Stanley believes that the news will have a positive reaction on the stock price, although HS-10535 has historically received little attention from investors, which may not significantly affect the valuation of HANSOH PHARMA.
Trump's tariff plan is unpopular! More than half of the USA population opposes imposing taxes on commodities from Mexico.
①The plan of the USA's incoming president Trump to impose tariffs does not seem to be popular among the public. According to a poll, 51% of USA voters oppose imposing tariffs on commodities from Mexico, Canada, and China; ②Standard & Poor's states that USA tariffs will increase inflation rates and reduce economic output, while some citizens and businesses are stockpiling goods due to tariff concerns, leading to a significant increase in throughput at the ports of Los Angeles and Long Beach in November.
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Living Stone : thank you
104437220 :
104799076 : JOHNNY
Leroy Collyear : How how does this benefit us common folk?
103964377 : Gold price
View more comments...